SUCHTUTORIUM ANZEIGENSuch-Tutorium anzeigen
(Benötigt Flash, öffnet sich in neuem Fenster) Show Tutorial VideoSuch-Tutorium anzeigen
(Benötigt Flash, öffnet sich in neuem Fenster)
Produktdetails

anti-B-cell CLL/lymphoma 10 (BCL10) Antikörper

Übersicht

Antigen: B-cell CLL/lymphoma 10 (BCL10)
Klonalität: Monoklonal (151)
Applikation: Immunhistochemie (IHC)
Reaktivität: Human
Wirt: Maus
3 Publikationen vorhanden 3 Publikationen vorhanden
Menge: 1ml (100ug/ml approximately) (Produktvarianten)
Preis: 294,61 €   (Zzgl. Versandkosten und MWSt)
Bestellnummer: ABIN125237
Verfügbarkeit: Lieferbar innerhalb von 5 Werktagen
Bestellhinweis Bestellhinweis
In den Warenkorb

Auf dieser Seite

Produktbeschreibung
Anwendungen
Publikationen
Verwandte Produkte
Protokolle

Kundenservice

Technische Anfrage stellen
Produktdetails an Kollegen senden
Datenblatt herunterladen

Produktbeschreibung  » anti-B-cell CLL/lymphoma 10 (BCL10) Antikörper

zurück nach oben ^


Antigen B-cell CLL/lymphoma 10 (BCL10)
Immunogen Human recombinant Bcl-10
Reaktivität Human
Wirt Maus
Klonalität Monoklonal
Isotyp IgG1 »Passende Sekundärantikörper
Klon 151
Spezifität Monoclonal Anti-Bcl-10 reacts specifically with human Bcl-10. The epitope recognized by the antibody resides within amino acids 122-168 of human Bcl-10 molecule. Bcl-10, also designated as CIPER, mE10, cE10, CARMEN, and CLAP, is an N-terminal CARD (Caspase Recruitment Domain) containing protein. It is a cellular homologue of the equine herpesvirus-2 protein E-10 (vCLAP). Bcl-10 was implicated in the regulation of apoptosis by interacting with caspase 9, enhancing procaspase 9 processing, and triggering its activation when overexpressed in the cell. Bcl-10 cellular overexpression induces JNK, p38, and NF-kB activation. Deregulation of Bcl-10 expression was also demonstrated to be involved in cellular oncogenesis.

Anwendungen  » anti-B-cell CLL/lymphoma 10 (BCL10) Antikörper

zurück nach oben ^


Applikation Immunhistochemie (IHC)
» Hier finden Sie 1 verfügbares Protokoll zu den getesteten Anwendungen
Applikationshinweise Titer/Working Dilution: This antibody may be diluted to a titer of 1:25-1:100 in an ABC method. However, depending on the staining conditions employed, we suggest that final dilution should be determined by the user. Staining Protocol: We suggest an incubation period of 30 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user. High temperature treatment of formalin-fixed tissue sections with 10mM citrate buffer, pH 6.0 must be performed prior to the immunostaining. Positive Control: Tonsil. Cellular localization: Nuclear
Konzentration 100ug/ml approximately
Buffer This antibody is supplied as purified immunoglobulin by protein G chromatography containing sodium azide as preservative.
Lagerung Store the antibody at 2-8o c. Do not use it beyond the expiration date stated on the label.
Forschungsgebiet Krebs
Beschränkungen Für Forschungszwecke. Als CE-zertifizierter Antikörper in der Europäischen Union für In Vitro Diagnostik (IVD) zugelassen.

Publikationen  » anti-B-cell CLL/lymphoma 10 (BCL10) Antikörper

zurück nach oben ^


Publikationen Willis, Jadayel, Du et al.: "Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types." In: Cell, Vol. 96, Issue 1, pp. 35-45, 1999 (PubMed)

Srinivasula, Ahmad, Lin et al.: "CLAP, a novel caspase recruitment domain-containing protein in the tumor necrosis factor receptor pathway, regulates NF-kappaB activation and apoptosis." In: The Journal of biological chemistry, Vol. 274, Issue 25, pp. 17946-54, 1999 (PubMed)

Du, Peng, Liu et al.: "BCL10 gene mutation in lymphoma." In: Blood, Vol. 95, Issue 12, pp. 3885-90, 2000 (PubMed)